Literature DB >> 9403314

Myocardial histological changes in dilated cardiomyopathy during a long-term left ventricular assist device support.

S Taketani1, Y Sawa, N Fukushima, T Masai, N Kawaguchi, S Onishi, H Matsuda.   

Abstract

As the myocardium in patients with dilated cardiomyopathy (DCM) is deteriorating progressively, resulting in a decrease in left ventricular function, patients with end-stage DCM may require implantation of a left ventricular assist device (LVAD) unless they undergo heart transplantation. Although LVAD has been reported to provide excellent hemodynamic support, no data are currently available about the effects of long-term LVAD support on the myocardium in patients with DCM. We describe two patients with end-stage DCM who underwent LVAD implantation and were supported with LVAD for 524 and 245 days, respectively. Serial myocardial biopsies showed increases in myocardial cell diameter and intercellular fibrosis, despite excellent hemodynamic support by LVAD. These data suggest that the myocardium in patients with end-stage DCM deteriorates progressively, even if the pre-load of the left ventricle is reduced by LVAD.

Entities:  

Mesh:

Year:  1997        PMID: 9403314     DOI: 10.1007/bf02820873

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  5 in total

1.  Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies.

Authors: 
Journal:  Br Heart J       Date:  1980-12

2.  Chronic mechanical circulatory support: rehabilitation, low morbidity, and superior survival.

Authors:  R L Kormos; S Murali; M A Dew; J M Armitage; R L Hardesty; H S Borovetz; B P Griffith
Journal:  Ann Thorac Surg       Date:  1994-01       Impact factor: 4.330

3.  Improved left ventricular function after chronic left ventricular unloading.

Authors:  O H Frazier; C R Benedict; B Radovancevic; R J Bick; P Capek; W E Springer; M P Macris; R Delgado; L M Buja
Journal:  Ann Thorac Surg       Date:  1996-09       Impact factor: 4.330

4.  The effect of prolonged left ventricular support on myocardial histopathology in patients with end-stage cardiomyopathy.

Authors:  S A Scheinin; P Capek; B Radovancevic; J M Duncan; H A McAllister; O H Frazier
Journal:  ASAIO J       Date:  1992 Jul-Sep       Impact factor: 2.872

5.  Structural and left ventricular histologic changes after implantable LVAD insertion.

Authors:  P M McCarthy; S Nakatani; R Vargo; K Kottke-Marchant; H Harasaki; K B James; R M Savage; J D Thomas
Journal:  Ann Thorac Surg       Date:  1995-03       Impact factor: 4.330

  5 in total
  5 in total

Review 1.  Building a bridge to recovery: the pathophysiology of LVAD-induced reverse modeling in heart failure.

Authors:  Shigeru Miyagawa; Koichi Toda; Teruya Nakamura; Yasushi Yoshikawa; Satsuki Fukushima; Shunsuke Saito; Daisuke Yoshioka; Tetsuya Saito; Yoshiki Sawa
Journal:  Surg Today       Date:  2015-04-04       Impact factor: 2.549

2.  Effects of the left ventricular assist device on the compliance and distensibility of the carotid artery.

Authors:  Danielle L Templeton; Ranjit John; Patricia Painter; Aaron S Kelly; Donald R Dengel
Journal:  Heart Vessels       Date:  2012-08-09       Impact factor: 2.037

3.  Cardiac unloading by LVAD support differentially influences components of the cGMP-PKG signaling pathway in ischemic and dilated cardiomyopathy.

Authors:  Sven Persoon; Michael Paulus; Stephan Hirt; Carsten Jungbauer; Alexander Dietl; Andreas Luchner; Christof Schmid; Lars S Maier; Christoph Birner
Journal:  Heart Vessels       Date:  2018-03-15       Impact factor: 2.037

4.  Morphological and molecular changes of the myocardium after left ventricular mechanical support.

Authors:  Hideo A Baba; Jeremias Wohlschlaeger
Journal:  Curr Cardiol Rev       Date:  2008-08

5.  Evidence for synergy between sarcomeres and fibroblasts in an in vitro model of myocardial reverse remodeling.

Authors:  Shi Shen; Lorenzo R Sewanan; Stuart G Campbell
Journal:  J Mol Cell Cardiol       Date:  2021-05-14       Impact factor: 5.763

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.